**Supplemental Materials**

**Figure 2 Classification of *Clostridium difficile* Infection Severity and Treatment Recommendations**

IDSA= Infectious Diseases Society of America (IDSA)

SHEA= Society for Healthcare Epidemiology of America

Scr= Serum Creatinine

PO= Per Os

IV= Intravenous

Q= Every

**Figure 3 *Clostridium difficile* Infection Best Practice Alert**

**Figure 4 *Clostridium difficile* Infection Guideline-based Treatment Prescribing**

**Table 2 Clinical Characteristics**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Pre BPA/Order Set****N=66** | **Post BPA/Order Set****N=65** |
| **Age at CDI diagnosis (Median (IQR))** | **57 (42-69)** | **60 (52-67)** |
| **Gender** **Female, n (%)** | **38 (57.6)** | **28 (43)** |
| **Risk Factors for CDI, n (%)****Immunocompromised** **Cancer\*****HIV****Immunosuppressant PTA****Antibiotics PTA** | **35 (53)****18 (27.3)****3 (4.5)****14 (21.2)****29 (43.9)** | **21 (32.3)****7 (10.8)****0 (0)****14 (21.5)****21 (32.3)** |
| **History of CDI, n (%)****1-2 previous occurrences****>2 occurrences**  | **3 (4.5)****2****1** | **10 (15.4)****9****1** |
| **Toxigenic CDI\*\*, n (%)** | **37 (56.1)** | **33 (50.7)** |
| **CDI Severity, n (%)****Mild-Moderate****Severe****Severe Complicated****Recurrent (>1 recurrence)** | **46 (69.7)****18 (27.3)****1 (1.5)****1 (1.5)** | **49 (75.4)****12 (18.5)****1 (1.5)****3 (4.6)** |
| **CDI Initial Treatment, n (%)****Metronidazole monotherapy****Vancomycin monotherapy****Metronidazole and vancomycin** **Fidaxomicin** | **46 (69.7)****14 (21.2)****5 (7.6)****1 (1.5)** | **49 (75.4)****7 (10.8)****9 (13.8)****0 (0)** |
| **CDI Treatment Duration** **(Median (IQR))** | **11 (6.75-14)** | **10 (8 - 14)** |

\*Active cancer treatment

BPA= Best Practice Alert

CDI= *Clostridium difficile* Infection

HIV= Human Immunodeficiency Virus

PTA= Prior to Admission

**\*\*** As determined by toxins A and B enzyme immunoassay